arrow
J

Jian Lei

Sichuan University
H指数:20
被引数:2,858

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

First-line anlotinib versus bevacizumab plus CapeOX in RAS/BRAF wild-type unresectable metastatic colorectal cancer (ANCHOR): a multicenter, prospective, randomized, phase 3 trial

ANCHOR研究:一线安罗替尼与贝伐珠单抗联合卡培他滨/奥沙利铂治疗RAS/BRAF野生型不可切除转移性结直肠癌的多中心、前瞻性、随机、III期临床试验

2026-09-010
OA
YL1004 is a SARS-CoV-2 papain-like protease inhibitor with immunomodulatory and antiviral activity in mice

YL1004是一种SARS-CoV-2的木瓜蛋白酶样蛋白酶抑制剂,在小鼠中具有免疫调节和抗病毒活性

2026-01-260
OA
Discovery of Highly Potent and Selective SOS1 Inhibitors for the Treatment of KRAS-Driven Colorectal Cancer

发现用于治疗KRAS驱动的结直肠癌的高效且选择性SOS1抑制剂

2026-01-010
PRE
Author Correction: An orally available Mpro/TMPRSS2 bispecific inhibitor with potent anti-coronavirus efficacy in vivo

作者更正:一种口服可用的Mpro/TMPRSS2双特异性抑制剂,具有体内强效抗冠状病毒疗效

2025-12-150
OAAI
The analysis of prognostic value of liver metastatic burden for non-functional pancreatic neuroendocrine tumors with synchronous liver metastasis after curative surgery: a retrospective study in a single center

肝脏转移负荷对同步肝转移的非功能性胰腺神经内分泌肿瘤术后预后的价值分析:一项单中心回顾性研究

2025-12-010
PRE
Intranasal vaccine combining adenovirus and trimeric subunit protein provides superior immunity against SARS-CoV-2 Omicron variant

鼻内疫苗结合腺病毒和三聚体亚单位蛋白为SARS-CoV-2 Omicron变种提供更优免疫力

2025-09-220
OAAI
An orally available Mpro/TMPRSS2 bispecific inhibitor with potent anti-coronavirus efficacy in vivo

一种口服可用的Mpro/TMPRSS2双特异性抑制剂,具有体内强效抗冠状病毒活性

2025-07-160
OA
A recombinant protein vaccine induces protective immunity against SARS-CoV-2 JN.1 and XBB-lineage subvariants

重组蛋白疫苗可诱导针对SARS-CoV-2 JN.1和XBB谱系亚变体的保护性免疫

2025-02-260
OA
Intranasal delivery of a subunit protein vaccine provides protective immunity against JN.1 and XBB-lineage variants

鼻内递送亚单位蛋白疫苗可提供针对JN.1和XBB谱系变体的保护性免疫

2024-11-200
OAAI
An orally available Mpro inhibitor is effective against wild-type SARS-CoV-2 and variants including Omicron
2022-04-270
PRE